Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells

被引:20
|
作者
Burks, Scott R. [1 ,2 ,3 ,5 ]
Macedo, Luciana F. [6 ]
Barth, Eugene D. [9 ,10 ]
Tkaczuk, Katherine H. [4 ,7 ]
Martin, Stuart S. [4 ,5 ]
Rosen, Gerald M. [1 ,2 ,3 ,8 ]
Halpern, Howard J. [9 ,10 ]
Brodie, Angela M. [4 ,6 ]
Kao, Joseph P. Y. [1 ,2 ,3 ,5 ]
机构
[1] Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA
[2] Univ Maryland, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA
[3] Univ Maryland, Ctr EPR Imaging In Vivo Physiol, Baltimore, MD 21201 USA
[4] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA
[6] Univ Maryland, Dept Pharmacol, Baltimore, MD 21201 USA
[7] Univ Maryland, Dept Med, Baltimore, MD 21201 USA
[8] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[9] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60657 USA
[10] Univ Chicago, Ctr EPR Imaging In Vivo Physiol, Chicago, IL 60657 USA
基金
美国国家卫生研究院;
关键词
Electron paramagnetic resonance spectroscopy; Imaging; Breast cancer; HER2; Liposomes; Nitroxides; MAMMARY-CARCINOMA; NITROXYL RADICALS; CANCER; OVEREXPRESSION; PROTOONCOGENE; AMPLIFICATION; NANOPARTICLES; TRASTUZUMAB; LIPOSOMES; MECHANISM;
D O I
10.1007/s10549-009-0715-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a concentration-dependent quenching of their EPR signal that is analogous to the self-quenching of fluorescent molecules. Therefore, intact liposomes encapsulating high concentrations of nitroxides exhibit greatly attenuated EPR spectral signals, and endocytosis of such liposomes represents a cell-activated contrast-generating mechanism. After endocytosis, the encapsulated nitroxide is liberated and becomes greatly diluted in the intracellular milieu. This dequenches the nitroxides to generate a robust intracellular EPR signal. It is therefore possible to deliver a high concentration of nitroxides to cells while minimizing background signal from unendocytosed liposomes. We report here that intracellular EPR signal can be selectively generated in a specific cell type by exploiting its expression of Human Epidermal Growth Factor Receptor 2 (HER2). When targeted by anti-HER2 immunoliposomes encapsulating quenched nitroxides, Hc7 cells, which are novel HER2-overexpressing cells derived from the MCF7 breast tumor cell line, endocytose the liposomes copiously, in contrast to the parent MCF7 cells or control CV1 cells, which do not express HER2. HER2-dependent liposomal delivery enables Hc7 cells to accumulate 750 mu M nitroxide intracellularly. Through the use of phantom models, we verify that this concentration of nitroxides is more than sufficient for EPR imaging, thus laying the foundation for using EPR imaging to visualize HER2-overexpressing Hc7 tumors in animals.
引用
收藏
页码:121 / 131
页数:11
相关论文
共 50 条
  • [1] Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells
    Scott R. Burks
    Luciana F. Macedo
    Eugene D. Barth
    Katherine H. Tkaczuk
    Stuart S. Martin
    Gerald M. Rosen
    Howard J. Halpern
    Angela M. Brodie
    Joseph P. Y. Kao
    Breast Cancer Research and Treatment, 2010, 124 : 121 - 131
  • [2] In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells
    Tahmasebi, Fathollah
    Kazemi, Tohid
    Amiri, Mohammad Mehdi
    Khoshnoodi, Jalal
    Mahmoudian, Jafar
    Bayat, Ali Ahmad
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Shokri, Fazel
    IMMUNOTHERAPY, 2014, 6 (01) : 43 - 49
  • [3] Anti-HER2 immunoliposomes for targeted drug delivery
    Hong, K
    Kirpotin, DB
    Park, JW
    Shao, Y
    Shalaby, R
    Colbern, G
    Benz, CC
    Papahadjopoulos, D
    ANTICANCER MOLECULES: STRUCTURE, FUNCTION, AND DESIGN, 1999, 886 : 293 - 296
  • [4] Anti-HER2 immunoliposomes for targeted drug delivery
    Park, JW
    Kirpotin, D
    Hong, K
    Colbern, G
    Shalaby, R
    Shao, Y
    Meyer, O
    Nielsen, U
    Marks, J
    Benz, CC
    Papahadjopoulos, D
    MEDICINAL CHEMISTRY RESEARCH, 1998, 8 (7-8) : 383 - 391
  • [5] Tumor targeting using anti-her2 immunoliposomes
    Park, JW
    Kirpotin, DB
    Hong, K
    Shalaby, R
    Shao, Y
    Nielsen, UB
    Marks, JD
    Papahadjopoulos, D
    Benz, CC
    JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) : 95 - 113
  • [6] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [8] Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
    Slaga, Dionysos
    Ellerman, Diego
    Lombana, T. Noelle
    Vij, Rajesh
    Li, Ji
    Hristopoulos, Maria
    Clark, Robyn
    Johnston, Jennifer
    Shelton, Amy
    Mai, Elaine
    Gadkar, Kapil
    Lo, Amy A.
    Koerber, James T.
    Totpal, Klara
    Prell, Rodney
    Lee, Genee
    Spiess, Christoph
    Junttila, Teemu T.
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (463)
  • [9] Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms
    Le, XF
    McWatters, A
    Wiener, J
    Wu, JY
    Mills, GB
    Bast, RC
    CLINICAL CANCER RESEARCH, 2000, 6 (01) : 260 - 270
  • [10] Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
    Bartsch, R.
    Berghoff, A.
    Pluschnig, U.
    Bago-Horvath, Z.
    Dubsky, P.
    Rottenfusser, A.
    DeVries, C.
    Rudas, M.
    Fitzal, F.
    Dieckmann, K.
    Mader, R. M.
    Gnant, M.
    Zielinski, C. C.
    Steger, G. G.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 25 - 31